Compare Charles River Laboratories Intl. Inc (CRL) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs DENTSPLY SIRONA Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.47 (market cap $14.23B), while DENTSPLY SIRONA Inc trades at $8.81 (market cap $1.73B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 8.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| CRL | XRAY | |
|---|---|---|
Market Cap | $14.23B | $1.73B |
Volume | 1,176,885 | 6,198,582 |
Sector | Health | Health |
52-Week High | $310.77 | $14.68 |
52-Week Low | $149.93 | $8.52 |
Typical Hold Time | 33 Days | 72 Days |
Enterprise Value | $17.06B | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
